

**TDMS No.** 20201 - 04  
**Test Type:** 26-WEEK  
**Route:** SKIN APPLICATION  
**Species/Strain:** MICE/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
TEF TRANSGENICS (PCB 126 / PECDF MIXTURE)  
**CAS Number:** TEFTGMIXTURE

**Date Report Reqsted:** 06/14/2006  
**Time Report Reqsted:** 15:55:10  
**First Dose M/F:** NA / 04/21/03  
**Lab:** BAT

**C Number:** C20201D  
**Lock Date:** 07/24/2004  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL

TDMS No. 20201 - 04

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

TEF TRANSGENICS (PCB 126 / PECDF MIXTURE)

CAS Number: TEFTGMIXTURE

Date Report Requested: 06/14/2006

Time Report Requested: 15:55:10

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	36/180 NG/KG	121/605 NG/KG	360/1800NG/KG	760/3800NG/KG
<b>Disposition Summary</b>					
Animals Initially in Study	20	20	20	20	20
Early Deaths					
Moribund Sacrifice	1	4	2	1	4
Natural Death	2	3	1	1	2
Survivors					
Moribund Sacrifice				1	
Terminal Sacrifice	17	13	17	17	14
Animals Examined Microscopically	20	20	20	20	20
<b>ALIMENTARY SYSTEM</b>					
Liver	(20)	(20)	(20)	(20)	(20)
Clear Cell Focus	1 (5%)				
Fatty Change	1 (5%)	2 (10%)	1 (5%)	7 (35%)	3 (15%)
Hematopoietic Cell Proliferation	1 (5%)		3 (15%)	8 (40%)	8 (40%)
Hepatodiaphragmatic Nodule	1 (5%)				
Inflammation	19 (95%)	19 (95%)	19 (95%)	19 (95%)	18 (90%)
Necrosis	7 (35%)	4 (20%)	11 (55%)	13 (65%)	5 (25%)
Pigmentation	10 (50%)	11 (55%)	9 (45%)	8 (40%)	14 (70%)
Tension Lipidosis					1 (5%)
Bile Duct, Hyperplasia				1 (5%)	
Hepatocyte, Degeneration					1 (5%)
Mesentery	(1)	(0)	(3)	(1)	(3)
Fat, Necrosis	1 (100%)		3 (100%)	1 (100%)	3 (100%)
Pancreas	(0)	(0)	(1)	(0)	(0)
Artery, Inflammation			1 (100%)		
Artery, Thrombosis			1 (100%)		
Salivary Glands	(1)	(0)	(0)	(1)	(1)
Stomach, Forestomach	(6)	(6)	(2)	(7)	(7)
Hyperplasia, Squamous		1 (17%)			
Stomach, Glandular	(1)	(0)	(0)	(0)	(0)
Glands, Hyperplasia	1 (100%)				
Tooth	(6)	(6)	(6)	(5)	(6)
Peridontal Tissue, Dysplasia					1 (17%)
Peridontal Tissue, Inflammation					1 (17%)

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 04  
Test Type: 26-WEEK  
Route: SKIN APPLICATION  
Species/Strain: MICE/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
TEF TRANSGENICS (PCB 126 / PECDF MIXTURE)  
CAS Number: TEFTGMIXTURE

Date Report Requested: 06/14/2006  
Time Report Requested: 15:55:10  
First Dose M/F: NA / 04/21/03  
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	36/180 NG/KG	121/605 NG/KG	360/1800NG/KG	760/3800NG/KG
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOPOIETIC SYSTEM					
Lymph Node	(0)	(1)	(0)	(1)	(2)
Hyperplasia, Lymphoid				1 (100%)	
Lymph Node, Mandibular	(0)	(1)	(1)	(1)	(2)
Hyperplasia, Lymphoid		1 (100%)			1 (50%)
Hyperplasia, Plasma Cell			1 (100%)	1 (100%)	
Lymph Node, Mesenteric	(1)	(1)	(1)	(0)	(0)
Hyperplasia, Lymphoid		1 (100%)	1 (100%)		
Spleen	(20)	(20)	(20)	(20)	(20)
Hematopoietic Cell Proliferation	3 (15%)	3 (15%)	9 (45%)	14 (70%)	16 (80%)
Thymus	(20)	(18)	(20)	(20)	(19)
Atrophy	3 (15%)	4 (22%)	4 (20%)	5 (25%)	9 (47%)
INTEGUMENTARY SYSTEM					
Skin	(4)	(7)	(10)	(9)	(8)
Fibrosis	1 (25%)				
Hemorrhage				1 (11%)	
Hyperplasia, Squamous	4 (100%)	3 (43%)	2 (20%)	3 (33%)	1 (13%)
Inflammation, Chronic Active	3 (75%)	1 (14%)	2 (20%)	3 (33%)	6 (75%)
Ulcer	1 (25%)			1 (11%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 04

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

TEF TRANSGENICS (PCB 126 / PECDF MIXTURE)

CAS Number: TEFTGMIXTURE

Date Report Requested: 06/14/2006

Time Report Requested: 15:55:10

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	36/180 NG/KG	121/605 NG/KG	360/1800NG/KG	760/3800NG/KG
Skin, Control Dermis	(20)	(20)	(20)	(20)	(20)
Inflammation, Chronic Active					5 (25%)
Skin, Site Of Application	(20)	(20)	(20)	(20)	(20)
Fibrosis	1 (5%)				
Hyperplasia, Mast Cell			1 (5%)	4 (20%)	3 (15%)
Hyperplasia, Squamous	1 (5%)	5 (25%)	16 (80%)	18 (90%)	15 (75%)
Inflammation, Chronic Active	2 (10%)	9 (45%)	19 (95%)	18 (90%)	20 (100%)
Ulcer				1 (5%)	
Skin, Soa No Mass	(20)	(20)	(19)	(11)	(10)
Hyperplasia, Mast Cell				1 (9%)	
Hyperplasia, Squamous	1 (5%)	8 (40%)	2 (11%)	6 (55%)	5 (50%)
Inflammation, Chronic Active	3 (15%)	3 (15%)	8 (42%)	7 (64%)	9 (90%)
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
Lung	(20)	(20)	(20)	(20)	(20)
Alveolar Epithelium, Hyperplasia		1 (5%)			
Alveolus, Infiltration Cellular, Histiocyte				1 (5%)	5 (25%)
Interstitialium, Inflammation	1 (5%)	1 (5%)	2 (10%)	2 (10%)	1 (5%)
Perivascular, Inflammation	2 (10%)	1 (5%)		2 (10%)	4 (20%)
Serosa, Inflammation, Chronic Active	7 (35%)	4 (20%)	2 (10%)	3 (15%)	2 (10%)
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
Kidney	(0)	(0)	(0)	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 04  
Test Type: 26-WEEK  
Route: SKIN APPLICATION  
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
TEF TRANSGENICS (PCB 126 / PECDF MIXTURE)  
CAS Number: TEFTGMIXTURE

Date Report Reqsted: 06/14/2006  
Time Report Reqsted: 15:55:10  
First Dose M/F: NA / 04/21/03  
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	36/180 NG/KG	121/605 NG/KG	360/1800NG/KG	760/3800NG/KG
--	---------	--------------	---------------	---------------	---------------

\*\*\* END OF REPORT \*\*\*